Company research
ACHIEVE LIFE SCIENCES, INC.
CIK 949858Updated Sep 27, 2026
SecurityACHV · NASDAQ · equity
Name history
ONCOGENEX PHARMACEUTICALS, INC. · through Jul 31, 2017SONUS PHARMACEUTICALS INC · through Aug 7, 2008
ACHV price & chart
Loading TradingView…
NASDAQ:ACHV on TradingView ↗About the company
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.
In the news
Achieve Life Sciences Announced Granting of New Hire Inducement Awards ↗
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 41,790,000Source | 38,633,000Source | 19,371,000Source | 29,971,000Source |
| Property, Plant and Equipment, NetUSD | 3,000Source | 8,000Source | 13,000Source | 4,000Source |
| GoodwillUSD | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,929,000Source | 12,753,000Source | 15,546,000Source | 24,771,000Source |
| Assets, CurrentUSD | 39,889,000Source | 36,467,000Source | 16,982,000Source | 27,330,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 2,107,000Source | 1,325,000Source | 2,454,000Source |
| Operating Lease, Right-of-Use AssetUSD | 64,000Source | 119,000Source | 66,000Source | 123,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 20,272,000Source | 17,734,000Source | 20,819,000Source | 21,668,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 121,000Source | 103,000Source | 90,000Source | 87,000Source |
| Retained Earnings (Accumulated Deficit)USD | -260,226,000Source | -205,578,000Source | -165,751,000Source | -135,936,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 10,000Source | 31,000Source | 4,000Source | 4,000Source |
| Stockholders' Equity Attributable to ParentUSD | 21,518,000Source | 20,899,000Source | -1,448,000Source | 8,303,000Source |
| Additional Paid in Capital, Common StockUSD | 281,613,000Source | 226,343,000Source | 164,209,000Source | 144,148,000Source |
| Liabilities and EquityUSD | 41,790,000Source | 38,633,000Source | 19,371,000Source | 29,971,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,082,000Source | 6,682,000Source | 20,813,000Source | 21,599,000Source |
| Operating Lease, Liability, CurrentUSD | 61,000Source | 55,000Source | 63,000Source | 58,000Source |
| Accounts Payable, CurrentUSD | — | 1,950,000Source | 618,000Source | 1,660,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,000Source | 66,000Source | 6,000Source | 69,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 36,400,000Source | 34,400,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,761,000Source | 5,325,000Source | 3,439,000Source | 3,270,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -49,465,000Source | -29,770,000Source | -24,479,000Source | -37,549,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 6,111,000Source | -21,580,000Source | -21,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,000Source | — | 21,000Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 0Source | 114,000Source | 220,000Source | 47,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 51,527,000Source | 48,527,000Source | 15,278,000Source | 19,295,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,176,000Source | -2,823,000Source | -9,225,000Source | -18,251,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 52,000Source | 23,000Source | — | — |
| Amortization of Intangible AssetsUSD | 200,000Source | 200,000Source | 200,000Source | 200,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 36,400,000Source | 34,400,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | -283,000Source | — | — |
| General and Administrative ExpenseUSD | — | 16,252,000Source | 11,436,000Source | 10,722,000Source |
| GoodwillUSD | 1,034,000Source | 1,034,000Source | 1,034,000Source | 1,034,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 819,000Source | 2,180,000Source | — | — |
| Investment Income, InterestUSD | 1,495,000Source | 2,356,000Source | 825,000Source | 199,000Source |
| Net Income (Loss) Attributable to ParentUSD | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Nonoperating Income (Expense)USD | 232,000Source | -758,000Source | -2,565,000Source | -1,550,000Source |
| Operating Lease, ExpenseUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Other Nonoperating Income (Expense)USD | -36,000Source | -30,000Source | -9,000Source | 40,000Source |
| Payments of Financing CostsUSD | — | — | — | 20,000Source |
| Payments to Acquire InvestmentsUSD | 24,755,000Source | 47,887,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Other Nonoperating Income (Expense)USD | -36,000Source | -30,000Source | -9,000Source | 40,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Net Income (Loss) Attributable to ParentUSD | -54,648,000Source | -39,827,000Source | -29,815,000Source | -42,350,000Source |
| Earnings Per Share, BasicUSD per share | -1.25Source | -1.24Source | -1.5Source | -4Source |
| Earnings Per Share, DilutedUSD per share | -1.25Source | -1.24Source | -1.5Source | -4Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 43,594,652Source | 32,071,146Source | 19,827,354Source | 10,593,034Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 43,594,652Source | 32,071,146Source | 19,827,354Source | 10,593,034Source |
| Interest Expense (non-operating)USD | 819,000Source | 2,180,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 200,000Source | 200,000Source | 200,000Source | 200,000Source |
| Costs and ExpensesUSD | 54,880,000Source | 39,069,000Source | 27,250,000Source | 40,800,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 228,000Source | 229,000Source | 228,000Source | 236,000Source |
| General and Administrative ExpenseUSD | — | 16,252,000Source | 11,436,000Source | 10,722,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -54,192,000Source | -39,532,000Source | -28,982,000Source | -41,660,000Source |
| Interest ExpenseUSD | — | — | 2,853,000Source | 1,789,000Source |
| Investment Income, InterestUSD | 1,495,000Source | 2,356,000Source | 825,000Source | 199,000Source |
| Nonoperating Income (Expense)USD | 232,000Source | -758,000Source | -2,565,000Source | -1,550,000Source |
| Operating Lease, ExpenseUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Research and Development ExpenseUSD | — | 22,817,000Source | 15,814,000Source | 30,078,000Source |
Filing attachments
achv-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 achv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board o…
Read attachment ↗d854692dex991.htm · 8-K · 2026-05-12
EX-99.1 2 d854692dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, …
Read attachment ↗achv-ex4_1.htm · 8-K · 2026-04-16
EX-4.1 2 achv-ex4_1.htm EX-4.1 EX-4.1 EXHIBIT 4.2 NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES INTO WHICH THE SECURITIES REPRESENTED HEREBY ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURIT…
Read attachment ↗achv-ex4_2.htm · 8-K · 2026-04-16
EX-4.2 3 achv-ex4_2.htm EX-4.2 EX-4.2 EXHIBIT 4.2 NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES INTO WHICH THE SECURITIES REPRESENTED HEREBY ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURIT…
Read attachment ↗achv-ex99_1.htm · 8-K · 2026-04-16
EX-99.1 6 achv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Achieve Life Sciences Announces Up to $354 Million Private Placement $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBENEWSWIRE) - Achieve Life Sciences, …
Read attachment ↗achv-ex99_1.htm · 8-K · 2026-03-24
EX-99.1 2 achv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24,2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc(Achieve) (Nasdaq: ACHV), a late-stage specialty phar…
Read attachment ↗